

Wilson MG, Dickie M, Cooper CL, Carvalhal A, Bacon J, Rourke SB. Treatment, Care and Support for People Co-Infected with HIV and Hepatitis C: A Scoping Review. Open Medicine 2009.

Reference list for included articles related to treatment

- (1) Fumaz CR, Muñoz-Moreno JA, Ballesteros AL, Paredes R, Ferrer MJ, Salas A et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. *AIDS Care* 2007;19(1):138-45.
- (2) Rodríguez TM, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández CA, González LE, Salgado MR et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfecting patients who failed previous IFN based therapy. *Journal of Clinical Virology* 2007;38(1):32-8.
- (3) Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N et al. Management of Chronic Hepatitis C: Consensus Guidelines. *Canadian Journal of Gastroenterology* 2007;21(Suppl C):25C-34C.
- (4) Al-Harhi L, Voris J, Du W, Wright D, Nowicki M, Frederick T et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfecting women: role of HCV on expression of primed/memory T cells. *Journal of Infectious Diseases* 2006;193(9):1202-10.
- (5) Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. *Journal of Viral Hepatitis* 2006;13(10):683-9.
- (6) Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT et al. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. *AIDS* 2006;20(3):323-31.
- (7) Brown LS, Jr., Kritz S, Chu M, Madray C. Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfecting with HIV and hepatitis C undergoing methadone maintenance. *Journal of Substance Abuse Treatment* 30(4):331-5, 2006 June.
- (8) De Rosa FG, Audagnotto S, Bargiacchi O, Garazzino S, Marucco DA, Veronese L et al. Resolution of HCV infection after highly active antiretroviral therapy in a HIV-HCV coinfecting patient. *Journal of Infection* 2006;53(5):e215-e218.
- (9) Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. *AIDS* 2006;20(8):1157-61.
- (10) Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaró J et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfecting patients with no early virological response. *Antiviral Therapy* 2006;11(4):473-82.

- (11) Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT et al. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. *AIDS* 2006;20(3):345-51.
- (12) Hare CB, Morris JA, Chu A, Gotz V, Loveland JJ, Hodes D et al. Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. *Pharmacoepidemiology & Drug Safety* 2006;15(2):71-6.
- (13) Hooshyar D, Napravnik S, Miller WC, Eron JJ, Jr. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care. *AIDS* 2006;20(4):575-83.
- (14) Miller CL, Spittal PM, Wood E, Chan K, Schechter MT, Montaner JSG et al. Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations. *AIDS Care* 2006;18(8):968-76.
- (15) Moreno A, Barcena R, Garcia-Garzon S, Moreno L, Quereda C, Muriel A et al. Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. *Journal of Viral Hepatitis* 2006;13(7):466-73.
- (16) Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. *Drug Alcohol Depend* 2006;84(2):188-94.
- (17) Patel MR, Mullen MP, Dieterich DT. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfecting with HIV and HCV genotype 1. *AIDS Reader* 2006;16(3):164.
- (18) Pau AK, McLaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottlilil S. Predictors for hematopoietic growth factors use in HIV/HCV-coinfecting patients treated with peginterferon alfa 2b and ribavirin. *AIDS Patient Care & STDs* 2006;20(9):612-9.
- (19) Santin M, Shaw E, Garcia MJ, Delejido A, de Castro ER, Rota R et al. Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. *AIDS Research & Human Retroviruses* 2006;22(4):315-20.
- (20) Schwarze-Zander C, Blackard JT, Zheng H, Addo MM, Lin W, Robbins GK et al. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfecting patients receiving HCV treatment: importance of the GBV-C genotype. *Journal of Infectious Diseases* 2006;194(4):410-9.
- (21) Solmone M, Girardi E, Lalle E, Abbate I, D'Arminio MA, Cozzi-Lepri A et al. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfecting patients according to the pattern of response to highly active antiretroviral therapy. *Antiviral Therapy* 2006;11(1):87-94.
- (22) Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfecting sustained virological responders from nonresponders. *HEPATOLOGY* 2006;43(5):943-53.
- (23) Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfecting patients. *Journal of Infection* 2006;53(1):36-42.



*Promoting excellence and innovation
in HIV research and care*

- (24) Weis N, Lindhardt BO, Kronborg G, Hansen AB, Laursen AL, Christensen PB et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: A nationwide cohort study. *Clinical Infectious Diseases* 2006;42(10):1481-7.
- (25) Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palù G et al. Short Statement of the First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients. *Journal of Hepatology* 2005;42(5):615-24.
- (26) Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. *Clinical Infectious Diseases* 2005;40(4):588-93.
- (27) Backus LI, Phillips BR, Boothroyd DB, Mole LA, Burgess J, Rigsby MO et al. Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes* 2005;39(5):613-9.
- (28) Bani-Sadr F., Carrat F, Rosenthal E, Piroth L, Morand P, Lunel FF et al. Spontaneous hepatic decompensation in patients coinfecting with HIV and hepatitis C virus during interferon-ribavirin combination treatment. *Clinical Infectious Diseases* 2005;41(12):1806-9.
- (29) Bani-Sadr F., Carrat F, Pol S, Hor R, Rosenthal E, Goujard C et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfecting patients during interferon plus ribavirin-based therapy. *Journal of Acquired Immune Deficiency Syndrome* 2005;40(1):47-52.
- (30) Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M et al. Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfecting patients on HAART. *Antiviral Therapy* 2005;10(2):309-17.
- (31) Caudai C, Pianese M, Zacchini F, Toti M, Zazzi M, Valensin PE. Longitudinal study in HIV/HCV-coinfecting HAART-naïve patients and role of HCV genotype. *Journal of Clinical Virology* 2005;32(2):151-5.
- (32) Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. *Journal of Acquired Immune Deficiency Syndromes* 2005;40(1):41-6.
- (33) Glesby MJ, Bassett R, Ston-Smith B, Fichtenbaum C, Jacobson EL, Brass C et al. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. *Journal of Infectious Diseases* 2005;191(5):686-93.
- (34) Khalili M, Bernstein D, Lentz E, Barylski C, Hoffman TM. Pegylated interferon a-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. *Digestive Diseases and Sciences* 2005;50(6):1148-55.
- (35) Legrand-Abrevanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. *Journal of Medical Virology* 2005;77(1):66-9.

- (36) Mehta SH, Thomas DL, Torbenson M, Brinkley S, Mirel L, Chaisson RE et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. *HEPATOLOGY* 2005;41(1):123-31.
- (37) Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. *AIDS Research & Human Retroviruses* 2005;21(9):743-52.
- (38) Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C et al. Lipid disorders in antiretroviral-naïve patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. *Journal of Antimicrobial Chemotherapy* 2005;55(5):800-4.
- (39) Moreno A, Barcena R, Garcia-Garzon S, Muriel A, Quereda C, Moreno L et al. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin. *Journal of Hepatology* 2005;43(5):783-90.
- (40) Nelson M, Matthews G, Brook MG, Main J, BHIVA Coinfection Guideline Committee on behalf of the British HIV Association. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection. *HIV Medicine* 2005;6(Suppl 2):96-106.
- (41) Núñez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E et al. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. *Antiviral Therapy* 2005;10(5):657-62.
- (42) Petoumenos K, Ringland C, Australian HIV Observational Database. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. *HIV Medicine* 2005;6(3):155-63.
- (43) Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. *Journal of Acquired Immune Deficiency Syndromes* 2005;39(4):401-5.
- (44) Restrepo A, Johnson TC, Widjaja D, Yarmus L, Meyer K, Clain DJ et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. *Journal of Viral Hepatitis* 2005;12(1):86-90.
- (45) Rodriguez TM, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: Results of a randomized clinical study. *Antimicrobial Agents and Chemotherapy* 2005;49(10):3997-4008.
- (46) Servin-Abad L, Molina E, Baracco G, Arosemena L, Regev A, Jeffers L et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. *Journal of Viral Hepatitis* 2005;12(4):429-34.
- (47) Sherman KE, Shire NJ, Rouster SD, Peters MG, James KM, Chung RT et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. *Gastroenterology* 2005;128(2):313-27.

- (48) Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S et al. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naïve HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. *Clinical Infectious Diseases* 2005;41(8):1186-95.
- (49) Soriano V, Ramos B, Nunez M, Barreiro P, Maida I, Garcia-Samaniego J et al. Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype. *Journal of Infectious Diseases* 2005;192(7):1245-8.
- (50) Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. *AIDS* 2005;19(6):585-92.
- (51) Thompson VV, Ragland KE, Hall CS, Morgan M, Bangsberg DR. Provider assessment of eligibility for hepatitis C treatment in HIV-infected homeless and marginally housed persons. *AIDS* 2005;19(Suppl 3):S208-S214.
- (52) Vigano A, Schneider L, Giacomet V, Bianchi R, Cicero ML, Soster F et al. Efficacy and tolerability of multiple drug therapy in HIV-infected children. *Journal of Infection* 2005;50(5):404-11.
- (53) Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. *Journal of Viral Hepatitis* 2005;12(2):207-11.
- (54) Adeyemi OM, Jensen D, Attar B, Ghaoui R, Gallagher M, Wolen D et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. *AIDS Patient Care & STDs* 2004;18(4):239-45.
- (55) Antonucci G, Antinori A, Boumis E, De Longis P, Gentile M, Girardi E. Guidelines for the management of HCV infection in HIV-infected persons. *Infez Med* 2004;12(1):7-18.
- (56) Arizcorreta A, Brun F, Fernandez-Gutierrez C, Garcia JR, Guerrero F, Perez-Guzman E et al. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. *Clinical Microbiology & Infection* 2004 December;10(12):1067-74.
- (57) Ballesteros AL, Franco S, Fuster D, Planas R, Martinez MA, Acosta L et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. *AIDS* 2004;18(1):59-66.
- (58) Ballesteros AL, Miro O, Lopez S, Fuster D, Videla S, Martinez E et al. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both. *Antiviral Therapy* 2004;9(6):969-77.
- (59) Benson CA, Kaplan JE, Masur H, Pau.A., Holmes KK, CDC et al. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/ Infectious Diseases Society of America. *Morbidity and Mortality Weekly Report* 2004;53(15):48-53.



*Promoting excellence and innovation
in HIV research and care*

- (60) Carrat F, Bani SF, Pol S, Rosenthal E, Lunel FF, Benzekri A et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2004;292(23):2839-48.
- (61) Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *New England Journal of Medicine* 2004;351(5):451-9.
- (62) Conway B, Prasad J, Reynolds R, Farley J, Jones M, Jutha S et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. *Clinical Infectious Diseases* 2004;38(Suppl 5):S402-S408.
- (63) French L, Benning L, Anastos K, Augenbraun M, Nowicki M, Sathasivam K et al. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: Impact of hepatitis C coinfection. *Clinical Infectious Diseases* 2004;39(3):402-10.
- (64) Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. *AIDS Research & Human Retroviruses* 2004;20(12):1293-7.
- (65) Kottlilil S, Polis MA, Kovacs JA. HIV Infection, hepatitis C infection, and HAART: hard clinical choices. *JAMA* 2004;292(2):243-50.
- (66) Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. *AIDS* 2004;18(13):F27-F36.
- (67) Macias J, Castellano V, Merchante N, Palacios RB, Mira JA, Saez C et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. *AIDS* 2004;18(5):767-74.
- (68) Manavi K, McMillan A. A significant proportion of HIV-infected patients admitted to hospital have immunosuppression as a result of failure of highly active antiretroviral therapy. *HIV Medicine* 2004;5(5):360-3.
- (69) Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. *HEPATOLOGY* 2004;40(1):120-4.
- (70) Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. *AIDS* 2004;18(13):F21-F25.
- (71) Meraviglia P, Schiavini M, Castagna A, Vigano P, Bini T, Landonio S et al. Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. *HIV Medicine* 2004;5(5):334-43.
- (72) Moreno L, Quereda C, Moreno A, Perez-Elias MJ, Antela A, Casado JL et al. Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. *AIDS* 2004;18(1):67-73.



*Promoting excellence and innovation
in HIV research and care*

- (73) Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. *AIDS* 2004 January 2;18(1):75-9.
- (74) Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. *Health Technology Assessment* 2004;8(39):1-125.
- (75) Sherman, M., Bain, V., Villeneuve, J-P., Myers, R. P., Cooper, C., Martin, S., and Lowe C. Management of Viral Hepatitis: A Canadian Consensus Conference 2003/2004. Health Canada and Correctional Service Canada; 2004.
- (76) Soriano V, Miro JM, Garcia-Samaniego J, Torre-Cisneros J, Nunez M, del RJ et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. *Journal of Viral Hepatitis* 2004;11(1):2-17.
- (77) Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A et al. Care of patients with hepatitis C and HIV co-infection. *AIDS* 2004;18(1):1-12.
- (78) Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, Management, and Treatment of Hepatitis C. *HEPATOLOGY* 2004;39(4):1147-71.
- (79) Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. *AIDS* 2004 November;18(17):2277-84.
- (80) Torriani FJ, Rodriguez TM, Rockstroh JK, Lissen E, Gonzalez GJ, Lazzarin A et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *New England Journal of Medicine* 2004;351(5):438-50.
- (81) Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. *HEPATOLOGY* 2004;39(2):311-7.
- (82) Johanson FD, Balliram DB. Successful treatment of hepatitis C in a patient with advanced AIDS and decompensated cirrhosis. *AIDS Reader* 2003;13(10):500-1.
- (83) Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes* 2003;33(3):365-72.
- (84) Lincoln D, Petoumenos K, Dore GJ, Australian HIV. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. *HIV Medicine* 2003;4(3):241-9.
- (85) Macias J, Pineda JA, Lozano F, Corzo JE, Ramos A, Leon E et al. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfecting with human immunodeficiency virus and hepatitis C virus. *European Journal of Clinical Microbiology & Infectious Diseases* 2003;22(11):675-80.

- (86) Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. *Journal of Acquired Immune Deficiency Syndromes*: JAIDS 33(5):577-84, 2003 August 15.
- (87) Neau D, Trimoulet P, Winnock M, Rullier A, Le BB, Lacoste D et al. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. *Clinical Infectious Diseases* 2003;36(12):1564-71.
- (88) Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.[see comment]. *AIDS* 2003;17(7):1023-8.
- (89) Salmon-Ceron D, Lassalle R, Pruvost A, Benech H, Bouvier-Alias M, Payan C et al. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfecting with HIV and hepatitis C virus: A CORIST-ANRS HC1 trial. *Clinical Infectious Diseases* 2003;36(10):1295-304.
- (90) Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. *Journal of Infectious Diseases* 2003;188(10):1498-507.
- (91) Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. *Journal of Viral Hepatitis* 2003;10(2):118-25.
- (92) Uberti-Foppa C, De BA, Morsica G, Galli L, Gallotta G, Boeri E et al. Pretreatment of chronic active hepatitis C in patients coinfecting with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes* 2003;33(2):146-52.
- (93) Aceti A, Pasquazzi C, Zechini B, De BC, LIVERHAART Group. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. *Journal of Acquired Immune Deficiency Syndromes* 2002;29(1):41-8.
- (94) Bonnet F, Lawson-Ayayi S, Thiebaut R, Ramanampamonjy R, Lacoste D, Bernard N et al. A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. *Clinical Infectious Diseases* 35(10):1231-7, 2002;35(10):1231-7.
- (95) Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfecting with hepatitis C virus and human immunodeficiency virus. *Clinical Infectious Diseases* 2002;34(9):1259-63.
- (96) De LA, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. *Archives of Internal Medicine* 2002;162(18):2125-32.
- (97) Gebo, K. A., Jenckes, M. W., Chander, G., Torbenson, M. S., Ghanem, K. G., Herlong, H. F., Sulkowski, M. S., El-Kamary, S. S., Harris, K. A., Guedelhoefer, O. C., and Bass, E. B. Management of chronic hepatitis C. Rockville, MD: Agency for Healthcare Research and Quality; 2002.



*Promoting excellence and innovation
in HIV research and care*

- (98) Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. *Archives of Internal Medicine* 2002;162(22):2545-56.
- (99) Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 coinfection. *Gut* 2002;51(4):601-8.
- (100) Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes* 2002;30(1):65-8.
- (101) Rancinan C, Neau D, Saves M, Lawson-Ayayi S, Bonnet F, Mercie P et al. Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? *AIDS* 2002;16(10):1357-62.
- (102) Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. *Journal of Infectious Diseases* 2002;186(10):1498-502.
- (103) Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. *HEPATOLOGY* 2002;35(1):182-9.
- (104) Trimoulet P, Neau D, Le BB, Rullier A, Winnock M, Galperine T et al. Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection. *Journal of Medical Virology* 2002;67(2):143-51.
- (105) Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. *Journal of Acquired Immune Deficiency Syndromes* 2001;27(3):245-50.
- (106) Hernandez LV, Gilson I, Jacobson J, Affi A, Puetz TR, Dindzans VJ. Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients. *Alimentary Pharmacology & Therapeutics* 2001;15(10):1627-32.
- (107) Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. *AIDS* 2001;15(10):1261-8.
- (108) Boucher, M. and Gruslin, A. The Reproductive Care of Women Living with Hepatitis C Infection. Society of Obstetricians and Gynaecologists of Canada; 2000. Report No.: 96.
- (109) Filippini P, Coppola N, Scolastico C, Liorre G, Nocera R, Sagnelli E et al. Can HCV affect the efficacy of anti-HIV treatment? *Archives of Virology* 2000;145(5):937-44.
- (110) French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. *HIV Medicine* 2000;1(2):107-15.



*Promoting excellence and innovation
in HIV research and care*

- (111) Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *Lancet* 2000;356(9244):1800-5.
- (112) Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. *JAMA* 2000;283(1):74-80.
- (113) Gavazzi G, Richallet G, Morand P, Bouchard O, Bosseray A, Leclercq P et al. Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfecting with HIV and HCV. *Pathologie-biologie* 1998;46(6):412-5.
- (114) John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? *AIDS* 1998;12(17):2289-93.